BTTX — Better Therapeutics Income Statement
0.000.00%
HealthcareHighly SpeculativeMicro Cap
- $0.00m
- $7.71m
Annual income statement for Better Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG |
| Status: | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||
| Research And Development | |||
| Unusual Expense / Income | |||
| Other Operating Expenses | |||
| Total Operating Expenses | 0.002 | 40.3 | 38.3 |
| Operating Profit | -0.002 | -40.3 | -38.3 |
| Total Net Non Operating Interest Income / Expense | |||
| Net Income Before Taxes | -0.002 | -40.5 | -39.8 |
| Provision for Income Taxes | |||
| Net Income After Taxes | -0.002 | -40.3 | -39.8 |
| Net Income Before Extraordinary Items | |||
| Net Income | -0.002 | -40.3 | -39.8 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||
| Income Available to Common Shareholders Including Extraordinary Items | |||
| Diluted Net Income | -0.002 | -40.3 | -39.8 |
| Diluted Weighted Average Shares | |||
| Basic EPS Including Extraordinary Items | |||
| Diluted EPS Including Extraordinary Items | |||
| Diluted EPS Excluding Extraordinary Items | |||
| Normalised Income Before Taxes | |||
| Normalised Income After Taxes | |||
| Normalised Income Available to Common Shareholders | |||
| Diluted Normalised EPS | -0 | -1.44 | -1.69 |
| Dividends per Share |